Pharmaceuticals
Pharmaceutical companies develop, produce and sell patent-controlled drugs. Research & Development (R&D) spending is high; the timescale from discovery to final regulatory approval can be 15 years or more, after which the drug can be sold under licence for a maximum of 20 years. The quality and market potential of drugs in the development pipeline define a company's profit growth potential, stock value and prospects. The industry is increasingly complex, facing ongoing demands for innovation plus increasing price pressure from governments. R&D is a driving force, but emphasis seems to have shifted from producing blockbuster drugs to protecting them, with implications for company size.
The traditional business model may not be able to deliver sustainable growth. Change is essential and some companies have already undertaken business (process) reorganisations like those of the early 1990's in the chemical and other industries.
Voorne Partners' experience in business (process) reorganisation and working with globalised companies with a large R&D component can help you meet the industry's challenges.
